Skip to main content
. 2023 Jun 21;21:209. doi: 10.1186/s12916-023-02877-9

Table 2.

Drugs assessed in this study

Drug Class Drug name
Selective serotonin reuptake inhibitor (SSRI)

citalopram

dapoxetine

escitalopram

fluoxetine

fluvoxamine

paroxetine

sertraline

Serotonin and norepinephrine reuptake inhibitor (SNRI)

venlafaxine

duloxetine

reboxetine

Atypical

mirtzaphine

vortioxetine

bupropion

trazodone

vilazodone

Tricyclic antidepressant (TCA)

amitriptyline

clomipramine

imipramine

lofepramine

nortriptyline

trimipramine

Monoamine oxidase inhibitor (MAOI)

tranylcypromine

phenelzine

isocarboxazid

moclobemide